Show simple item record

dc.contributor.authorCleary, A
dc.contributor.authorWalsh, F
dc.contributor.authorConnolly, H
dc.contributor.authorHays, V
dc.contributor.authorOluwole, B
dc.contributor.authorMacken, E
dc.contributor.authorDowling, M
dc.date.accessioned2013-09-30T11:01:07Z
dc.date.available2013-09-30T11:01:07Z
dc.date.issued2012
dc.identifier.citationCleary A, Walsh F, Connolly H, Hays V, Oluwole B, Macken E, Dowling M. (2012) Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service. Journal of Psychiatric and Mental Health Nursing, 19(5), 395-401.en_GB
dc.identifier.urihttp://hdl.handle.net/10147/302493
dc.description.abstractThe aim of this audit was to review current practice within a rural mental health service area on the monitoring and documentation of side effects of antipsychotic depot medication. Following a review of the literature on best practice internationally, an evidence based audit tool was adapted. A sample of 60 case files, care plans and prescriptions were audited between January and May 2010. This represented 31% of the total number of service users receiving depot injections in the mental health service region (n=181). The audit results revealed that most service users had an annual documented medical review and a documented prescription. However, only 5 (8%) case notes examined had documentation recorded describing the condition of the injection site and alternation of the injection site was recorded in only 28 (47%) case notes. No case notes examined had written consent to commence treatment recorded, and only 3 (5%) of case notes had documented that information on the depot injection and side effects was given. In 57 (95%) of case notes no documentation of recorded information on the depot and on side effects was given. Documentation of physical observations and tests revealed that 58% of cases had full blood count, liver function tests, thyroid function tests and fasting lipids recorded. All other tests (i.e. temperature, pulse, respirations, blood pressure, ECG) were recorded in less than 50% of cases. Prolactin levels were not recorded in any case. The lack of written consent was partly attributed to lack of recording of consent. The failure to monitor and record some blood tests was partly attributed to a lack of clarity regarding whose responsibility it was. A standardised checklist has been developed as a result of the audit and this will be introduced by all teams across the service.
dc.languageeng
dc.language.isoenen
dc.publisherJournal of Psychiatric and Mental Health Nursingen_GB
dc.subjectMENTAL HEALTHen_GB
dc.subjectAUDITen_GB
dc.subjectMEDICATIONen_GB
dc.subjectMENTAL HEALTH SERVICESen_GB
dc.subject.otherMULTIDISCIPLINARY TEAMen_GB
dc.subject.otherADHERENCE TO MEDICATIONen_GB
dc.subject.otherANTI-PSYCHOTIC MEDICATIONen_GB
dc.titleMonitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service.en_GB
dc.typeArticleen
dc.identifier.journalJournal of Psychiatric and Mental Health Nursingen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
refterms.dateFOA2018-08-23T07:58:15Z
html.description.abstractThe aim of this audit was to review current practice within a rural mental health service area on the monitoring and documentation of side effects of antipsychotic depot medication. Following a review of the literature on best practice internationally, an evidence based audit tool was adapted. A sample of 60 case files, care plans and prescriptions were audited between January and May 2010. This represented 31% of the total number of service users receiving depot injections in the mental health service region (n=181). The audit results revealed that most service users had an annual documented medical review and a documented prescription. However, only 5 (8%) case notes examined had documentation recorded describing the condition of the injection site and alternation of the injection site was recorded in only 28 (47%) case notes. No case notes examined had written consent to commence treatment recorded, and only 3 (5%) of case notes had documented that information on the depot injection and side effects was given. In 57 (95%) of case notes no documentation of recorded information on the depot and on side effects was given. Documentation of physical observations and tests revealed that 58% of cases had full blood count, liver function tests, thyroid function tests and fasting lipids recorded. All other tests (i.e. temperature, pulse, respirations, blood pressure, ECG) were recorded in less than 50% of cases. Prolactin levels were not recorded in any case. The lack of written consent was partly attributed to lack of recording of consent. The failure to monitor and record some blood tests was partly attributed to a lack of clarity regarding whose responsibility it was. A standardised checklist has been developed as a result of the audit and this will be introduced by all teams across the service.


Files in this item

Thumbnail
Name:
Cleary2012Pre-peer.pdf
Size:
214.5Kb
Format:
PDF
Description:
Author's Pre-peer review version ...

This item appears in the following Collection(s)

Show simple item record